Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open …
R Dummer, PA Ascierto, HJ Gogas, A Arance… - The Lancet …, 2018 - thelancet.com
Background Encorafenib plus binimetinib and encorafenib alone improved progression-free
survival compared with vemurafenib in patients with BRAF V600-mutant melanoma in the …
survival compared with vemurafenib in patients with BRAF V600-mutant melanoma in the …
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open …
R Dummer, PA Ascierto, HJ Gogas, A Arance… - The Lancet …, 2018 - sonar.ch
METHODS COLUMBUS was a two-part, randomised, open-label, phase 3 study done at 162
hospitals in 28 countries. Eligible patients were aged at least 18 years with histologically …
hospitals in 28 countries. Eligible patients were aged at least 18 years with histologically …
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open …
R Dummer, PA Ascierto, HJ Gogas, A Arance… - The Lancet …, 2018 - Elsevier
Background Encorafenib plus binimetinib and encorafenib alone improved progression-free
survival compared with vemurafenib in patients with BRAF V600-mutant melanoma in the …
survival compared with vemurafenib in patients with BRAF V600-mutant melanoma in the …
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open …
R Dummer, PA Ascierto, HJ Gogas, A Arance… - The Lancet …, 2018 - europepmc.org
Background Encorafenib plus binimetinib and encorafenib alone improved progression-free
survival compared with vemurafenib in patients with BRAF V600-mutant melanoma in the …
survival compared with vemurafenib in patients with BRAF V600-mutant melanoma in the …
[引用][C] Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre …
R Dummer, P Ascierto, H Gogas, A Arance… - THE LANCET …, 2018 - research.unipg.it
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib
versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised …
versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised …
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open …
R Dummer, PA Ascierto, HJ Gogas… - The Lancet …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Encorafenib plus binimetinib and encorafenib alone improved progression-free
survival compared with vemurafenib in patients with BRAF V600-mutant melanoma in the …
survival compared with vemurafenib in patients with BRAF V600-mutant melanoma in the …
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open …
R Dummer, PA Ascierto, HJ Gogas, A Arance… - Lancet …, 2018 - zora.uzh.ch
BACKGROUND: Encorafenib plus binimetinib and encorafenib alone improved progression-
free survival compared with vemurafenib in patients with BRAFV600-mutant melanoma in …
free survival compared with vemurafenib in patients with BRAFV600-mutant melanoma in …
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open …
R Dummer, PA Ascierto, HJ Gogas, A Arance… - The Lancet …, 2018 - folia.unifr.ch
METHODS COLUMBUS was a two-part, randomised, open-label, phase 3 study done at 162
hospitals in 28 countries. Eligible patients were aged at least 18 years with histologically …
hospitals in 28 countries. Eligible patients were aged at least 18 years with histologically …
[引用][C] Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre …
R Dummer, PA Ascierto, HJ Gogas, A Arance… - The Lancet …, 2018 - cir.nii.ac.jp
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib
versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised …
versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised …
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open …
R Dummer, PA Ascierto, HJ Gogas, A Arance… - The Lancet …, 2018 - thelancet.com
Background Encorafenib plus binimetinib and encorafenib alone improved progression-free
survival compared with vemurafenib in patients with BRAF V600-mutant melanoma in the …
survival compared with vemurafenib in patients with BRAF V600-mutant melanoma in the …